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Abstract
Glioblastoma (GBM) is a highly invasive brain neoplasia with an elevated 
recurrence rate after surgical resection. The CyclinD1 (Ccnd1)/Cdk4–RB1 axis 
is frequently altered in GBM, leading to over-proliferation by RB1 deletion or by 
Ccnd1/Cdk4 over-activation. By not so well understood mechanisms, high 
levels of Ccnd1-Cdk4 also promote GBM cell invasion. The purpose of this work 
is to elucidate the in vivo role of the cytoplasmic Ccnd1-Cdk4 activity in the 
dissemination of GBM. We show that Ccnd1 activates invasion of primary 
human GBM cells through cytoplasmic RB1-independent mechanisms. By using 
GBM mouse models, we have observed that evaded GBM cells showed 
cytoplasmic Ccnd1 co-localizing with regulators of cell invasion such as RalA 
and Paxillin. Our genetic data strongly suggest that, in GBM cells, the 
Ccnd1/Cdk4 complex is acting upstream of those regulators. Accordingly, 
expression of Ccnd1 induces FAK, RalA and Rac1 activities. Finally, in vivo 
experiments demonstrated that the expression of a membrane-targeted Ccnd1 
form expanded the GBM dissemination. We conclude that Ccnd1-Cdk4 activity 
promotes GBM dissemination through cytoplasmic and RB1-independent 
mechanisms. Therefore, the inhibition of Ccnd1-Cdk4 activity may be useful to 
hinder dissemination of recurrent GBM.
Keywords: Glioblastoma, Cyclin D1, Cytoplasm, Migration, Tumor dissemination
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Introduction
Diffuse gliomas are the most frequent tumors in adult brain and are 
characterized by an extensive infiltration in brain parenchyma [1]. Among them, 
Glioblastoma (GBM) is the most common and aggressive (grade IV) and shows 
a median survival of 15 months [2,3]. In recent years, to achieve a most 
accurate classification and to increase diagnostic and predictive outcomes, a 
broad experimental pursuit has been to elucidate genetic and epigenetic 
alterations involved in diffuse glioma etiology and development [4–10]. For 
instance, we now know that a recurrent point mutation (R132H) in the isocitrate 
dehydrogenase 1 gene (IDH1) is mostly associated to low grade diffuse gliomas 
and a better prognosis [4,9–11]. All these genomic researches have brought 
about a new classification of diffuse gliomas based on molecular fingerprints 
together with histological grading [12]. In this classification, GBMs are divided in 
IDH-wildtype and IDH-mutant. Most GBM cases (90%) are IDH-wildtype, 
predominate in elderly patients and have poor prognosis. The remaining GBMs 
are IDH-mutant, are less aggressive with better prognosis, predominate in 
younger patients and evolved from a low grade glioma (secondary GBMs). In 
addition to the IDH status, there are other markers associated with specific 
subsets of patients. For instance, p53, ATRX and H3K27M mutations as well as 
the CpG island methylator phenotype are also used as prognosis markers for 
GBM [8,10].  
At present, regardless of the molecular characteristics, the standard treatment 
of patients with GBM includes surgical resection, radiotherapy and 
chemotherapy with temozolomide [13], an alkylating drug whose effects can be 
alleviated by DNA repair enzymes. A significant number of patients show 
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intrinsic resistance to temozolomide due to the expression of an 
alkyltransferase encoded by the MGMT gene [14]. When the MGMT promoter is 
unmethylated, the expression of this DNA repair gene confers resistance to 
alkylating agents. Alternatively, patients with methylated MGMT promoter are 
sensitive to temozolomide [15,16].  
After the treatment, recurrences are most likely due to incomplete resections of 
the infiltrated tumor. GBMs show specific histological patterns of invasion 
formed by the interaction of the tumor cells with their immediate environment 
[17,18]. For instance, cell migration along white matter tracts or blood vessels 
(perivascular) is frequently observed in biopsies.  
Cyclin-dependent kinases 4 and 6 (Cdk4/6) are part of one of the core 
pathways more frequently altered in GBM [5,8]. D-type cyclins (Ccnd) 
complexed with Cdk4/6 kinases phosphorylate and inhibit Retinoblastoma 
protein (RB1) in the nucleus, thus promoting cell cycle entry and proliferation 
[19]. The activity of Ccnd-Cdk4/6 complexes can be hindered by the Cdk-
inhibitors p16 (CDKN2A), p15 (CDKN2B) and p18 (CDKN2C). The most 
frequent alterations leading to the activation of the Cdk4/6 pathway in GBM are 
co-deletions of CDKN2A and CDKN2B loci (56%), amplification of CDK4 locus 
(14%) and deletion of RB1 locus (7.9%) [8]. The detection and analysis of these 
mutations are relevant for prognosis. For instance, the presence of homozygous 
deletions in CDKN2A and B loci drastically reduces the overall survival of IDH-
mutant gliomas irrespective of whether they are grade III astrocytic tumors or 
GBMs [20].  In xenograft models, GBM growth is significantly reduced after 
treatment with pharmacological inhibitors of Cdk4/6 activity [21,22]. However, 
RB1 non-expressing GBMs are resistant to this treatment [23,24].  
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The movement of invading cells along the extracellular matrix requires the 
coordination of different processes. Invading cells have to detach themselves 
partially from the matrix and, at the same time, to extend protrusions such as 
lamellipodia to undergo migration [25]. The knockdown (KD) of Ccnd1 in 
macrophages and fibroblasts stimulates a reduction in the levels of adhesion 
and spreading on fibronectin plates and, at the same time, increases cell 
migration and invasion capacities [26,27]. Also, Ccnd1 downregulation in GBM 
cell lines not only attenuates their proliferation but also their invasiveness 
[28,29]. Contrasting with the nuclear role of Ccnd1-Cdk4 in the regulation of 
proliferation, the control of cell invasiveness by Ccnd1-Cdk4 involves 
cytoplasmic mechanisms and targets [30,31]. In a previous work, we have 
described that cytoplasmic Ccnd1-Cdk4 promotes invasion in mouse fibroblasts 
and rat tumor cells through the phosphorylation of the focal adhesion 
component Paxillin (Pxn) and the Ral GTPase Exchange Factor (GEF) Rgl2 
[30,32]. Ccnd1-Cdk4 induces the phosphorylation of Pxn at serine 83 [30], 
which is involved in Focal Adhesion Kinase (FAK) and Rac1 activation [33]. On 
the other hand, Rgl2 activation promotes accumulation of Ral-GTP [34].  
The purpose of this work is to reveal the importance of cytoplasm-associated 
Ccnd1 activity in the invasive properties of primary human tumor cells. We show 
that cytoplasmic Ccnd1-Cdk4 plays a role in the dissemination of GBM in vivo. 
Materials and Methods 
Cell culture methods
GBM cell lines U251-MG and U87-MG were obtained from ATCC. Cell line 
authentication was carried out by comparing the STR profile with the reference 
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cell line in ATCC (Cell line authentication service, StabVida). Cells were 
maintained in DMEM media containing 10% FBS, penicillin/streptomycin at 
37°C and 5% CO2 atmosphere. Palbociclib (Selleckchem) was used at a final 
concentration of 2 μM or 5 μM. Primary GBM cell cultures were isolated  as 
previously described [35]. We finally managed to establish 12 primary cultures, 
10 GBM and 2 astrocytoma (grade II), and characterized Ccnd1, Cdk4, RB1 
and IDH1 status in all of them. For further studies, we have used three strains 
with different RB1 and CDKN2A status: GBM65 (RB1-defective; CDKN2A-
wildtype), GBM6 (RB1-wild type; CDKN2A-defective) and GBM55 (RB1-
wildtype; CDKN2A-wildtype). Proliferation, viability, spreading and invasion 
assays were adapted from previously described protocols [30] and are detailed 
in Supplementary Methods. For experiments using Palbociclib, we treated the 
cells with the inhibitor for 12 h before the experiment.
Expression vectors
Human CCND1, mouse Pxn and human Rgl2 were used to obtain an N-terminal 
3×HA fusion under UBI or CMV promoters in a lentiviral vector derived from 
pDSL (Invitrogen). Site-directed mutagenesis primers were used to obtain the 
different mutant alleles of the above genes as described in Supplementary 
Methods.
The dominant-negative allele RalBS28N was obtained from Addgene (CJ 
Der). Plasmid pMmCcnD1 was obtained from MRC (Image ID 3155470).
Immunofluorescence (IF) and Immunohistochemistry (IHC)
Cells were washed in PBS and fixed in 4% paraformaldehyde (PFA) for 15 min 
at RT. Fixed GBM cells were permeabilized with 0.2% Triton-X-100 for 3 min at 
RT, and blocked with 3% Bovine Serum Albumin (BSA). For tissue 
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immunofluorescence, fixed mouse brains were treated with 30% sucrose 
overnight, included in Tissue Freezing medium (EMS 72592) and kept at -80ºC. 
Slides of 20 m were prepared in a cryostat and stored at -80ºC until use. 
Samples were transferred to RT and permeabilized with Methanol-Acetone at -
20ºC. In both protocols, primary antibodies were combined with adequate 
Alexa488 and/or Alexa594-labelled secondary antibodies. Nuclei were stained 
with Hoescht. For GFP staining, we performed a sandwich with two secondary 
Alexa488 antibodies (goat anti-rabbit and rabbit anti-goat) to increase the 
signal. Images were acquired using 40X and 60X objectives in an Olympus 
FV1000 confocal system and EVOS microscope. Primary antibodies are 
described in supplementary material, Table S1.
Details of IHC in paraffin blocks can be found in Supplementary Methods. A 
Tissue MicroArray (TMA) containing 20 samples of GBM and 20 samples of 
Astrocytoma (TMA-324) was obtained from the Spanish National Cancer 
Research Center (CNIO) Biobank. 
Immunoblotting and Ral pull-down assay
For immunoblot, protein samples were resolved by SDS-PAGE, transferred to 
PVDF membranes (Millipore), and incubated with primary antibodies (Table 
S1). Appropriate peroxidase (HRP)-linked secondary antibodies (GE 
Healthcare) were detected using the chemiluminescent HRP substrate 
Immobilon Western (Millipore). Chemiluminescence was recorded with a 
ChemiDoc-MP imaging system (BioRad).  Ral activity was analyzed by 
measuring the GTP-bound form of Ral. The assays were performed by using 
RalBP1 agarose (Upstate, cat# 14-415) according to the manufacturer's 
instructions (see Supplementary Methods). 
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Studies in humans and animals statement
Human samples for primary cultures were provided by the Biobank of IRBLleida 
authorized by the Department of Health of Catalonia and registered in the 
National Register of Biobanks of the Carlos III Institute of Health with 
B.0000682 reference number. The study was conducted following the principles 
of the Declaration of Helsinki (World Medical Association, 1964) and with the 
approval of the Ethics Committee for Scientific Research (CEIC) of HUAV-UdL. 
Studies involving experiments with animals were subjected to approval by the 
Commission of Animal Experimentation (CEA), pursuant to Decree 214/1997 
and Royal Decree 53/2013, from the Spanish law on the use of animals for 
experimentation and other scientific purposes. The experiments were performed 
in the animal facility of the University of Lleida (L-registration number 9900005). 
Mouse models
Immunodeficient SCID hr/hr male mice (12-week-old; 20–25 g) were maintained 
in specific pathogen free conditions, and were injected with 5×105 U87 
luciferase-expressing cells by intracranial injection in the subventricular zone of 
the right hemisphere (2 mm left to Bregma, 1 mm anterior to Coronal suture, 3 
mm depth). Depending on the experiment, animals were euthanized 21 or 28 
days after cell injection, brains were analyzed by bioluminescence and 
fluorescence, and finally fixed with PFA; a sample was included in paraffin for 
hematoxylin–eosin (H&E) staining and immunohistochemistry analysis. 
Luciferine was injected in the animals and the signal was recorded with a 
PhotonIMAGER and the software Photo-Acquisition. Image analysis was 
carried out in M3VisionTM.
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In the gliomagenesis model, tumors were generated by the injection of RCAS-
hPDGF viruses in neonatal mice (Nestin/tv-a;Cdkn2a-/-). Samples were 
obtained from mice as previously described [36]. 
Statistical analyses
Two-tailed t-test allowing unequal variance or Mann-Whitney test were used 
(*P<0.05, **P<0.01, ns no significant). Comparisons among groups were made 
by one way ANOVA and Tukey-HSD post-test. Throughout the paper error bars 
indicate SEM except in Fig. 4E (mean ± SD). In Fig. 4D mean values and 
confidence limits for a proportion were calculated. Analyses of results obtained 
from mice are detailed in Supplementary Methods.
Results
RB1-independent functions of cyclin D1 regulate the invasion efficiency of 
GBM cells.
To address the importance of the Ccnd1-Cdk4-RB1 regulatory pathway in 
human GBM, first we analyzed the expression levels of Ccnd1, Cdk4 and RB1 
in primary GBM cells, grade II astrocytoma cells as well as in U251-MG and 
U87-MG GBM cell lines (Figure 1A). All the GBM samples showed expression 
of Ccnd1 and Cdk4, most displaying higher levels than the low-grade 
astrocytoma samples and GBM cell lines. In contrast, RB1 expression exhibited 
different levels among GBM samples and was not detected in two of these 
(GBM65 and GBM66). The Cdk4 specific inhibitor Palbociclib impinges upon 
the proliferation rate of GBM cells only when RB1 is present [22–24]. Hence, in 
order to confirm lack of RB1 expression in GBM65, we tested the growth rate of 
these cells after inhibition of Cdk4 activity with Palbociclib as compared to the 
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RB1-positive strain GBM6. As expected, Palbociclib abated the growth rate of 
the GBM6 strain (Figure 1B) but had no effect on the growth of GBM65 (Figure 
1C). 
The original tumors of GBM65 (RB1-negative) and two RB1-positive samples 
GBM55 and GBM6 were further characterized by IHC to determine the IDH1 
and CDKN2A (p16INKA) status. All these samples belonged to IDH1 wild type 
group of GBM (supplementary material, Figure S1). Regarding the CDKN2A 
status, positive staining for p16INKA was present in GBM65 and GBM55 but it 
was not observed in the GBM6 sample (supplementary material Figure S1). 
Then, GBM6 cells could support higher Ccnd1-Cdk4 activity than GBM55 and 
GBM65 due to the absence of this cell cycle inhibitor. Next, we also tested the 
MGMT-promoter methylation status of GBM6 and GBM65 samples 
(supplementary material, Figure S2A). In accordance with their methylation 
status, only GBM65 cells expressed MGMT and were consequently resistant to 
Temozolomide (supplementary material, Figure S2B and S2C). 
Finally, to test the importance of Ccnd1-Cdk4 activity on GBM invasiveness, we 
determined the efficiency of invasion of RB1-negative (GBM65) and RB1-
positive (GBM6 and GBM55) primary GBM cells. Interestingly, GBM cell 
invasion capacity was clearly reduced by Palbociclib regardless of RB1 status 
(Figure. 1D and supplementary material, Figure S3A and S3C), whereas cell 
viability was not affected by the treatment with the inhibitor (Figure. 1E and 
supplementary material, Figure S3B and S3D). Similarly, the knockdown of 
Ccnd1 reduced the invasion efficiency of both RB1-negative (GBM65) and RB1-
positive (GBM6, U251-MG and U87-MG) cells (Figure. 1F and supplementary 
material Figure S3E-H), whereas it increased spreading on fibronectin plates 
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(Figure 1G and supplementary material Figure S3I and S3J). We conclude that 
Ccnd1-associated activity promotes cell invasion and reduces adhesion in 
primary GBM cells independently of RB1. Our data also suggest that Ccnd1-
Cdk4 inhibition efficiently reduced invasiveness of GBM cells in different 
CDKN2A and MGMT-expression backgrounds.  
Localization of the Ccnd1-Cdk4 activity in GBM cells.
By using patient derived glioma-tissue microarrays (TMA), we further confirmed 
that Ccnd1 expression is higher in GBM than in grade I and II astrocytoma 
biopsies (Figure 2A and 2B) [37,38]. However, only a small proportion of cells 
showed clear cytoplasmic signal for Ccnd1 (Figure 2C). This result was not 
completely unexpected as in other solid tumors Ccnd1 is preferentially 
accumulated in the cytoplasm of cells located at the invasive fronts [39]. Then, 
to better analyze Ccnd1 localization during GBM invasion, we have used a 
mouse model of gliomagenesis, which allows us to visualize the dissemination 
of tumor cells along the entire brain [36]. We infected neonatal Nestin/tv-a 
Cdkn2-/- mice with an RCAS retroviral vector expressing human PDGF. At four 
months of age, these mice showed human-like proneural GBM (Figure 2D) [36]. 
We found a strong nuclear signal for Ccnd1 in these tumors, but interestingly 
we also detected GBM cells containing cytoplasmic Ccnd1 that were escaping 
outside the tumor (Figure 2E). These cells also showed positive PDGF 
receptor (PDGFR) staining, a marker of proneural-like tumor cells [36]. 
To characterize further the localization of Ccnd1 in the invasive GBM cells, we 
next used a xenograft model wherein human GBM cells (U87-MG) were 
injected into the brains of SCID mice. To determine the localization of Ccnd1, 
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U87-MG cells were infected with lentiviral particles harboring an HA-Ccnd1 
construct (supplementary material, Figure S4B). Three weeks after the injection, 
mice developed intracranial tumors. We have observed that a high proportion of 
cells in the tumor mass showed HA-Ccnd1 accumulated in the nucleus (Figure 
3A and 3C). In contrast, most of the evaded cells (such as perivascular cells) 
exhibited a sharp cytoplasmic signal for HA-Ccnd1 (Figure 3B and 
supplementary material, Figure S4A). Moreover, Ccnd1 also co-localized with 
cytoplasmic targets such as Pxn [30] and RalA [32] in the cytoplasm and 
membranes of primary GBM cells (Figure 3D and E and supplementary 
material, Figure S4C). These results reinforce the idea that cytoplasmic Ccnd1 
could promote invasion of human GBM cells through the regulation of Pxn and 
Ral GTP activity.
Ccnd1 promotes FAK, Rac1 and RalA activation in human GBM cells.
To study the Ccnd1/Cdk4-Pxn-FAK-Rac1 axis in human GBM, first we 
determined the impact of Ccnd1 expression on FAK activation. Expression of 
Ccnd1 in GBM65 cells stimulated the phosphorylation of FAK at tyrosine 397 
(Figure 4A and 4B), a key event in FAK activation.
Next, we analyzed the levels of Rac1 activation in GBM cells with YFP-PBD, a 
construct that is a fluorescent biosensor of Rac1 activity [40] because the p21-
binding domain of PAK1 (PBD) specifically binds to Rac1-GTP forms. There 
were fewer cells with accumulation of YFP signal in the membrane or protrusion 
tips in the GBM sample knocked down for Ccnd1 (Figure 4C and 4D). This was 
indicative of lesser Rac1 activity associated to the membranes in the absence 
of Ccnd1.
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Finally, we determined RalA activity in GBM cells in different Ccnd1-expression 
conditions. By pull-down assays, we have observed an increase of active Ral 
(Ral-GTP) in cells expressing high levels of Ccnd1 (Figure 4E). Overall, our 
data indicate that Ccnd1-associated activity promotes the induction of the Pxn-
FAK-Rac1 and Ral pathways in primary GBM cells. These observations suggest 
that this axis may be implicated in the cytoplasmic functions of Ccnd1 in GBM 
cell invasion
Ccnd1 promotes invasion in human GBM cells through the stimulation of 
Rac1, FAK and RalA activities.
Next, we used genetic approaches to dissect the role of Pxn and Ral GTPases 
as mediators of Ccnd1 signaling in GBM cells. We first infected GBM65 cells 
either with an allele of Pxn (Pxn S83A S178A) that cannot be phosphorylated by 
Ccnd1-Cdk4 or with a dominant negative allele of RalA (RalAS31N) (Figure 5B). 
GBM cells expressing these mutant alleles were less invasive than wild-type 
cells, suggesting that active Pxn and Ral pathways are required for GBM 
invasion (Figure 5A). In a second experiment, we infected GBM65 cells with a 
phosphomimetic allele of Pxn (S83E S178E) or with an Rgl2-CAAX construct, a 
RalGTPase activator targeted to cell membranes (Figure 5D). Then, we tested 
the invasion capacity of these cells after inhibition of Ccnd1-Cdk4 activity with 
Palbociclib. In the presence of these hyperactive alleles, the inhibition of Ccnd1-
dependent activity produced a much more modest reduction in the invasion 
capacity of these cells than in wild-type cells (Figure 5C). This result is 
consistent with Ccnd1-Cdk4 regulating invasion of GBM65 cells through Pxn 
and Ral pathways. 
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We also tested the dependence of GBM-cell adhesion on Ccnd1, Pxn and Ral 
activities. U251-MG cells stably expressing the interfering RNA against human 
Ccnd1 (depleted of human Ccnd1) were transfected with mouse Ccnd1-GFP 
and, either a non-phosphorylatable Pxn allele (S83A S178A) or a dominant 
negative allele of RalB (RalBS28N). Cells expressing Ccnd1-GFP required 
more time to spread on fibronectin. However, this delay was not observed in the 
presence of inactive alleles of Pxn or Ral GTPase (Figure 5E), which suggests 
that Ccdn1 also regulates the adhesion of GBM cells through Pxn and Ral 
pathways.
To envisage the clinical relevance of cytoplasmic Ccnd1-associated activity, we 
have analyzed the frequency of genetic alterations for the cytoplasmic targets of 
Ccnd1-Cdk4. We have used the TCGA dataset of diffuse gliomas (GBM-LGG) 
from the GlioVis platform to obtain the data [41]. Interestingly, we have 
observed that an increment in gene copy number of RAC1 and RALA genes 
was linked with IDH wild type (“high-grade”) gliomas (supplementary material, 
Figures S5A and S5B). Consequently, the activation of cytoplasmic targets of 
Ccnd1-Cdk4, RAC1 and RALA, appears associated with glioma 
aggressiveness. In accordance with the relevance of Ccnd1-Ck4 activity in 
glioma aggressiveness [20], we have also observed that only an increment in 
CCND1 gene dosage reduced IDH mutant (“low-grade”) glioma survival 
(supplementary material, Figure S5C).
Accumulation of Ccnd1 in cell membranes promotes GBM dissemination 
in vivo.
In a previous work, we fused the farnesylation site of K-Ras protein (CAAX) to 
the C-terminus of Ccnd1, creating in this way a Ccnd1 that associates to cell 
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membranes and promotes Ral activation and cell invasion in prostate and 
endometrium tumor cell lines [39]. In this work, we have expressed Ccnd1-
CAAX in GBM cells and observed that the treatment with Palbociclib drastically 
reduced the invasion capacity of those cells (supplementary material, Figure 
S3I). This result suggests that inhibiting cytoplasmic Ccnd1 would reverse the 
invasive phenotype in GBM cells. 
 To test whether membrane-associated Ccnd1 promotes GBM dissemination in 
vivo, luciferase-expressing U87-MG cells were co-infected with lentiviral vectors 
expressing GFP and either Ccnd1-CAAX or wild-type Ccnd1. Cells were 
intracranially injected, and four weeks later mice were euthanized. The 
localization and size of the tumors were analyzed by bioluminescence (Figure 
6A). Tumors harboring Ccnd1-CAAX exhibited distant nodes from the original 
tumor (Figures 6B and 6C) and showed disseminated groups of tumor cells (cell 
foci) into the surrounding brain tissue (Figures 6F and 6G). Conversely, control 
tumors remained for the most part encapsulated (Figures 6H and 6I). By ki67 
staining, we determined that the proliferative status of the induced tumors were 
not significantly different regardless of the Ccnd1 allele expressed (Figures 6D 
and 6E). To evaluate tumor dissemination, we defined three areas (proximal, 
intermediate and distal) around the tumor mass (supplementary material, 
Figures S6A and S6B). We calculated the number of cell foci in each area 
(supplementary material, Figure S6C). Only those tumors that showed 
intermediate and distal cell foci were considered disseminated tumors. By these 
criteria, the total number of dispersed tumors was significantly increased in 
Ccnd1-CAAX samples (Figure 6J). Furthermore, we confirmed that Ccnd1-
CAAX was localized in the cell membrane of evaded tumor cells 
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(supplementary material, Figure S7). Overall, these results indicate that the 
accumulation of Ccnd1 in the membrane of GBM cells promotes GBM 
dissemination in vivo. 
Discussion
Cytoplasmic Ccnd1-Cdk4 plays a role in the dissemination of GBM in vivo. 
Taking advantage of xenograft and RCAS-Tva models, we find that Ccnd1 is 
cytoplasmic mainly in evaded GBM cells but not within the tumor masses, and 
that the imposed accumulation of Ccnd1 at the cell membranes significantly 
increases the number of evaded cells away from the tumor mass. The findings 
presented here are in line with a number of works showing that Ccnd1 
functionally interacts with cytoplasmic targets involved in the regulation of cell 
adhesion and invasion such as Filamin A, Pacsin, Rgl2 and Paxillin [30– 32,42]. 
Also, cytoplasmic Ccnd1 has been found at the invasive fronts of solid tumors 
[39] and the invasive blastoid variant of mantle cell lymphoma [43], suggesting 
an important role of cytoplasmic Ccnd1 in tumor invasion. Moreover, the 
accumulation of Ccnd1 at the cell membranes increases the metastatic potential 
of endometrial tumor cells in a lung-metastasis mouse model [39].  
These findings may have clinical implications. Upon Ccnd1-Cdk4 inhibition, we 
have observed similar reduction of invasiveness in IDH wild-type cells with 
different CDKN2A, MGMT-methylation and RB1 backgrounds, highlighting that 
inhibition of Cdk4/6-activity may be a useful approach to reduce dissemination 
in a broad spectrum of gliomas. Of note, since GBM cell invasion is RB1-
independent, the capacity of invasion of GBM cells is still sensitive to a 
Palbociclib treatment in the absence of RB1. This is in accordance with 
previous findings showing that the regulation of cell motility and invasion by 
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Ccnd1 in mouse fibroblasts is also RB1-independent [27]. In our xenograft 
experiments most tumors expressing membrane-associated Ccnd1 show GBM 
dissemination; yet, their proliferation ratio is similar to tumors expressing wild-
type Ccnd1, emphasizing that the regulation of GBM cell invasion by Ccnd1 is 
unconnected to the proliferative status.  
Our genetic data also indicate that Pxn is a downstream target of Ccnd1-Cdk4 
in human GBM cells. Interestingly, Pxn seems to behave as an oncogene in 
glioma progression and its overexpression is associated with high-grade 
gliomas [44]. Also, a positive correlation among GBM invasiveness and Pxn 
phosphorylation at tyrosine 118 has been reported [45]. Here, we contribute 
with genetic approaches to demonstrate that phosphorylation of Pxn at S83 and 
S178 is required for efficient invasion and inefficient spreading of GBM cells. 
Conceivably, these phosphorylations triggered by Ccnd1 expression could 
constitute an initial step in the induction of GBM invasion. While specific 
phosphoPxn S83 (S85 in humans) and S178 antibodies for human cells are not 
available, we have observed that expression of Ccnd1 activates downstream 
targets of Pxn such as FAK and Rac1. Of note, the importance of these 
downstream targets in GBM invasion has also been reported by different 
authors [1,46,47]. For instance, in GBM cell lines, loss of FAK inhibits EGF-
induced invasion [48], whereas Rac1 hyperactivation correlates with an 
elevated invasive phenotype [49,50].  
Furthermore, the expression of a RalA dominant-negative allele reduced the 
invasion efficiency of primary GBM cells. Ral GTPases are regulators of exocyst 
formation and the secretory pathway, and are involved in the control of cell 
growth and invasion [34]. Furthermore, Ral activation also contributes to Ras-
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driven transformation, and it is increased in many different types of cancer [51]. 
Surprisingly, very few data exist about the importance of Ral GTPases in GBM. 
Our results are consistent with a previous report showing that the knockdown of 
RalB decreases the invasiveness of human GBM cell lines [52]. 
We propose a model in which the cytoplasmic accumulation of Ccnd1-Cdk4 
activity causes cell evasion in GBM through the activation of the Pxn-Fak-Rac1 
axis and Ral GTPases (Figure 6K). Interestingly, cytoplasmic Ccnd1 has also 
been detected in human GBM recurrences after surgery and therapy [53]. 
Because Palbociclib inhibits both the nuclear and the cytoplasmic activities of 
Ccnd1-Cdk4, we propose that it does not only hinder cell proliferation in the 
presence of RB1, but also interferes with tumor dissemination independently of 
RB1 by precluding the cytoplasmic Ccnd1-Cdk4 activity. Then, it is conceivable 
to use the pharmacological inactivation of Ccnd1-Cdk4 as treatment not only 
against tumor cell proliferation but also against their invasive capacity. While 
additional work is required to address specifically the relevance of the 
cytoplasmic functions of Ccnd1-Cdk4 in glioma classification and outcome 
predictions, altogether, our results are in agreement with those works that 
sustain a clinical relevance of D-type cyclins and Cdk4/6 in the diagnosis and 
therapy of glioma [10,20]. 
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Figure legends
Figure 1. Ccnd1 regulates the efficiency of cell invasion and adhesion 
independently of RB1. A) Immunoblot to detect Ccnd1, Cdk4 and RB1 in 
primary GBMs, low grade gliomas and, U251-MG and U87-MG GBM cell lines. 
Actin staining was used as loading control. B and C) Respectively, the same 
number of RB1-positive (GBM6) and RB1-negative (GBM65) cells were treated 
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with the Ccnd1-Cdk4 inhibitor Palbociclib (5 M) (time 0) and total cell number 
was determined after 36 and 72 hours (n=3). D) RB1-negative GBM65 cells 
were incubated in the presence of Palbociclib (5 M) in a transwell device 
coated with matrigel. After 8 hours of incubation, invading cells were counted 
(n=3). E) Viable and total cells in D were counted (n=3). The ratio of viable 
(trypan-blue negative) to total cells is drawn. F) GBM65 cells were infected with 
scramble (scr) or shRNA anti-Ccnd1 (shD1) and the invasion efficiency tested 
as in D (n=5). The lower panel shows the levels of Ccnd1 and actin as a loading 
control. G) RB1-negative GBM65 cells infected with scramble (scr) or shRNA 
anti-Ccnd1 (shD1) were seeded on fibronectin plates, incubated for 30 minutes, 
and both spread and total cells were counted (n=3). For all the experiments, 
data are the mean ± SEM, and statistical significance was determined by 
student-t test. *(p≤0.05) ** (p≤0.01) ns = not significant.
Figure 2. Expression and localization of Ccnd1 in GBMs. A) Representative 
Ccnd1 staining of Glioma samples from the Tissue MicroArray (TMA). B) 
Boxplot representing the proportion of Ccnd1-positive cells from samples of low-
grade astrocytoma and GBM. Significance was determined by Mann–Whitney U 
test (p=0.022). C) Representative image of GBM cells expressing cytoplasmic 
Ccnd1. Arrows indicate cells with cytoplasmic localization. D and E) Images 
from immunohistochemical analyses with the indicated antibodies and H&E 
from a selected region of a RCAS hPDGF-driven tumor. The images 
correspond to consecutive slices. Boxes show an enlarged region. Scale bars, 
100 m.
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Figure 3. Ccnd1 localizes in the cytoplasm of GBM cells and co-localizes with 
Pxn and RalA. A) U87-MG cells infected with lentiviral particles containing a 
3HA-Ccnd1 were injected into the brains of SCID mice to initiate intracranial 
tumors. Three weeks after injection, brains were cryopreserved and processed 
for IF. Anti-HA (green) and anti-Glut1 (red) antibodies were used for the 
detection of HA-Ccnd1 and blood vessels, respectively. Images were acquired 
by confocal microscopy (10 m bar). Nuclei were stained with Hoescht (blue). 
The white contour designates regions with tumor cells. B) Representative image 
of evaded cells in A. C) From three independent mouse brains, we counted the 
number of infected cells (green) showing nuclear accumulation of HA-Ccnd1. 
Data are the mean ± SEM, and statistical significance (n=3) was determined by 
student-t test (** p≤0.01).  D and E) Cells were seeded on fibronectin plates for 
two hours, then fixed in 4% PFA and permeabilized with 0.2% Triton X-100. 
Images were acquired by confocal microscopy (10 m bar). Nuclei were stained 
with Hoescht (blue). Antibodies were: Anti-Ccnd1 (green), anti-Pxn (red) in D 
and anti-RalA (red) in E. 
Figure 4. Ccnd1 stimulates Fak, Rac1 and RalA activation in human GBM cells. 
A) Ccnd1-knockdown GBM65 cells (shD1) were transfected with mouse Ccnd1 
(MmD1, n=9) or GFP (n=6). Cells were maintained in low serum for 16 hours 
before collecting samples. FAK Y397, -Actin and Ccnd1 were determined by 
immunoblot. B) The levels of protein were determined by densitometry with the 
Image-Lab 4.0.1 software from Bio-Rad. -Actin was used as a loading control. 
Data are expressed as mean ± SEM. Significance was determined by a t-test. 
C) GBM65 cells were infected with interference RNA against Ccnd1 or with a 
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scrambled RNA as a control. Once Ccnd1 was downregulated, cells were 
transfected with the YFP-PBD construct (a sensor of Rac1 activity). Two days 
after transfection, cells were seeded on fibronectin for 2 h prior fixation and 
processing (10 m bar). Arrows indicate membrane regions with accumulation 
of YFP. D) The experiment in C was independently repeated twice. Mean 
values and confidence limits (=0.05; n≥100) are plotted. E) Ccnd1-knockdown 
GBM65 cells (shD1) were transfected with mouse Ccnd1 (MmD1) or GFP. 
Twenty-four hours later, active RalA-GTP was affinity purified with RalBP-beads 
from cell lysates. RalA-GTP and total RalA were detected by immunoblotting. 
RalBP-beads are shown as pull-down control. The experiment was repeated 
twice. Relative mean values ± SD for the RalA-GTP/total RalA ratios are shown. 
Figure 5. Ccnd1 promotes invasion of human GBM cells through Paxillin 
phosphorylation and Ral activation. A) GBM65 cells were infected with wild-type 
Pxn, a non-phosphorylatable Pxn allele or the dominant negative allele 
RalAS31N. Forty eight hours later, cells were se ded on 24-well transwell filters 
previously coated with matrigel, and allowed to invade for seven hours. Values 
are expressed as mean ± SEM (n=3). Significance was determined by one way 
ANOVA and Tukey-HSD post-test (*p<0.05). B) Immunoblots showing the 
expression of Pxn and Ral alleles (rat anti-HA) in the infected cells in A. Actin 
was used as a loading control. C) GBM65 cells were infected with a 
phosphomimetic Pxn allele or with Rgl2-CAAX. The invasion efficiency was 
tested as in A but cells were also treated with Palbociclib (5 M), or DMSO as a 
control. D) Immunoblots showing the expression of Pxn and Ral alleles (rat anti-
HA) in the infected cells in C. Actin was used as a loading control. E) U251 cells 
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stably expressing shD1 were transfected with GFP as a control (vector) or with 
Ccnd1-GFP, and then co-transfected with the non-phosphorylatable Pxn allele 
(S83A S178A) or with the dominant negative allele RalBS28N. Percentage of 
spreading was determined as in Figure 1G. Values are expressed as mean ± 
SEM (n=3). Significance was determined by one way ANOVA and Tukey-HSD 
post-test (**p<0.01).
Figure 6. Membrane-targeted Ccnd1 induces GBM dissemination in vivo. 
Human U87-MG cells stably expressing luciferase were co-infected with 
lentiviruses harboring GFP and Ccnd1-CAAX, Ccnd1, or an empty vector 
(control). Infected cells were inoculated intracranially in immunodeficient SCID 
male mice. For the experiment, we have finally used in total 27 mice, nine for 
each condition. Mice were euthanized four weeks after intracranial injection with 
these infected cells. Brains were processed for cryopreservation. To detect 
tumor cells (green), serial slides of the brain were immunostained with a rabbit 
anti-GFP antibody conjugated with Alexa Fluor-488 (from Invitrogen). The 
mouse brain (red) was contrasted with a secondary anti-mouse Alexa Fluor-594 
antibody (from Invitrogen). A) Tumor location and size was observed by 
luciferine-mediated luminescence. B) Representative image of a tumor 
expressing Ccnd1-CAAX showing disseminated nodules (arrows). C) 
Luminescence and GFP pictures showing a contralateral nodule in sample 2.2. 
D) Representative pictures of Ki67 staining immunosatining. E) Percentage of 
Ki67-positive cells (mean ± SEM, n=5 for each condition). F and G) Images 
from a tumor expressing Ccnd1-CAAX showing evaded tumor cells (arrow). H 
and I) Images from an encapsulated-control tumor. J) Plot showing the number 
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of disseminated versus non disseminated tumors (n=9 for each condition). The 
statistical significance was calculated with a Fisher’s exact test (*p<0.05; 
**p<0.01). K) A diagram of the proposed Ccnd1-Cdk4 regulatory network in 
GBM cells.
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Supplementary Figure 1. IDH1 and CDKN2A status. Slides of the original 
tumors of GBM6, GBM55 and GBM65 were processed for IHC analyses. IDH1 
status was tested with a mouse monoclonal antibody against the IDH1 R132H 
point mutation (DIA-H09, Dianova). A positive IDH1 mutant specimen was used 
as a positive control. CDKN2A status was tested with a mouse monoclonal 
antibody against p16INKa (E6H4, Roche). 
Supplementary Figure 2. MGMT promoter methylation status. A) The 
methylation status of the MGMT promoter was resolved in primary GBM samples 
and cell lines by pyrosequencing after bisulfite treatment. B) The expression of 
MGMT was determined in GMB6 and GBM65 cells by immunoblot. -actin was 
used as a loading control. C) The primary GBM cells were treated with the 
alkylating drug Temozolomide 100 M (TMZ) and cell growth was determined by 
MTT staining after ten days of treatment (n=4). Data are the mean ± SEM, and 
statistical significance was determined by one-ANOVA test (*** p≤0.001). 
Supplementary Figure 3. Ccnd1-Cdk4 activity regulates the efficiency of cell 
invasion in GBM cells. A and C). GBM cells were incubated in the presence of 
Palbociclib (2M) in a transwell device coated with matrigel at 37ºC and 5% CO2. 
After eight hours of incubation, invading cells were counted (n=3) B and D). Cells 
in A and C were incubated with Palbociclib (2M) for eight hours, and after this 
time, viable and total cells were counted (n=3). The ratio of viable (trypan-blue 
negative) cells versus total cells is drawn.  E)  U251-MG cells were infected with 
scramble (scr) or with two different shRNA anti-Ccnd1 (shD138 and shD139) and 
the invasion efficiency tested as in A (n=4). F) The downregulation of Ccnd1 in E 
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was tested by immunoblot. Actin was used as a loading control. G and H) U87-
MG and GBM6 cells were respectively infected with scramble (scr) or with the 
shRNA anti-Ccnd1 shD138 and the invasion efficiency tested as in A (n=3). I) 
GBM65 cells were infected with Ccnd1-CAAX and incubated in a transwell device 
coated with matrigel at 37ºC and 5% CO2. Palbociclib (5M) was added. After 
eight hours of incubation, invading cells were counted (n=3). J and K) U251-MG 
and U87-MG cells were infected with shD138 or with a scramble shRNA as a 
control. To test spreading, cells were seeded in serum-free medium in fibronectin-
coated plates. Thirty minutes later the proportion of spread cells was determined 
and plotted (n=4).  For all the experiments, data are the mean ± SEM and 
statistical significance was determined by student-t test. *(p≤0.05) ** (p≤0.01). ns 
= not significant.
Supplementary Figure 4. Ccnd1 co-localizes with Pxn and RalA in the 
cytoplasm and membranes of GBM cells. A) U87-MG cells infected with 3HA-
Ccnd1 were injected into the brains of SCID mice. Three weeks after injection, 
samples were processed for IF. The antibodies used were anti-HA (green) and 
anti-Glut1 (red) for the detection of blood vessels (red). Images were acquired by 
confocal microscopy (10m bar). Nuclei were stained with Hoescht (blue). B) The 
topical expression of Ccnd1 in A was tested by immunoblot with anti-Ccnd1. Actin 
was used as a loading control. C) Cells were seeded in fibronectin plates for 24 
hours, then fixed in 4% PFA and permeabilized with 0.2% Triton X-100. Images 
were acquired by confocal microscopy (10m bar). Nuclei were stained with 
Hoescht (blue). The antibodies used were Anti-Ccnd1 (green), anti-Pxn and anti-
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RalA (red). D) Cells incubated only in the presence of secondary antibodies were 
used as a control. 
Supplementary Figure 5. Relevance of cytoplasmic Ccnd1-associated activity 
in gliomas outcome. A) and B) Analysis of the genetic status of RAC1 (A) and 
RALA (B) genes from a TCGA cohort of diffuse gliomas (Gliovis). The 
percentages of the different alterations in IDH wild-type and mutant gliomas were 
plotted. C) From the same population than in A, we selected a subset of IDH 
mutant gliomas that were wild-type diploids for CDK4/6, CCND1/2/3, RAC1, 
RALA and CDKN2A/B (CDKN2A/B wt; n=176). Then, we have analyzed survival 
times (months) with a Kaplan-Meier plot comparing the effects of a copy number 
increase of CCND1 (gain; n=14) and homozygous deletion of CDKN2A/B 
(homodel; n=14). Hetloss, heterozygous loss; Diploid, wild type alleles; and Amp, 
amplification. 
Supplementary Figure 6. Quantification of GBM dissemination in vivo. A and B) 
we have defined three areas (P-proximal, I-intermediate and D-distal) around the 
tumor mass to estimate the extent of tumor dissemination. C) Plot showing the 
number of cells foci at different areas outside the tumor mass. Data are the mean 
± SEM (n=9 for each condition). The statistical significance was calculated with a 
Kruskal-Wallis test (* p<0.05). 
Supplementary Figure 7. Ccnd1-CAAX localizes in the membrane of human 
U87-MG cells in intracranial induced tumors. Human U87-MG cells were infected 
with lentiviruses harboring HA-Ccnd1-CAAX (A) or HA-Ccnd1 (B). These cells 
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were inoculated by intracranial injection in nude SCID mice, and three weeks later 
mice were sacrificed. Brains were obtained and included in paraffin for IHC 
detection. H&E staining was used to visualize the induced tumor. Ccnd1 
localization was detected with a rat monoclonal anti-HA and nuclei were stained 
with hematoxylin. 
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Supplementary Table S1
Antibody Reference IHC1 IF2 IB3
Anti-Ccnd1 Rabbit monoclonal clone EP12, Dako 
#M3642
Ready to use 1/2005 -
Anti-Ccnd1 Mouse monoclonal DCS-6, BD 
Pharmigen #556470
- - 1/500
Anti-Pxn Mouse monoclonal 349, BD 
Biosciences #610051
- 1/200 -
Anti-RalA Mouse monoclonal 8, BD Pharmigen 
#610222
- 1/200 1/2000
Anti-HA Rat monoclonal clone 3F10, Roche 
11867423001
1/400 1/2005 -
Anti-Glut1 Mouse monoclonal SPM498, 
Thermofisher #MA-11315
- 1/2005 -
Anti-GFP Rabbit polyclonal, Invitrogen A21311 - 1/2005 -
Anti-Ki67 Clone MIB-1, Agilent tecnhonogies-
DAKO.
Ready to use - -
Anti-
phosphoFAK 
(Tyr 397)
Rabbit polyclonal, Clone 31H5L17, 
Thermofisher #700255
1/100 - 1/5004 
Anti-Cdk4 Rabbit polyclonal C-22, SantaCruz 
#sc-260
- - 1/250
Anti-RB Mouse monoclonal G3-245, BD 
Pharmigen #554136
- - 1/500
Anti-Actin Mouse monoclonal Clone C4, 
Millipore #MAB1501R
- - 1/1000
Anti-Rac1 Mouse monoclonal 102, BD 
Pharmigen #610222
- - 1/2000
Anti-IDH1 
R132H
Mouse monoclonal H09, Dianova 
DIAH09
Ready to use - -
Anti-p16INKa Mouse monoclonal E6H4, Roche 
CINtec® Histology Kit
Ready to use - -
Anti-MGMT Mouse monoclonal MT3.1, Millipore 
MAB16200
- - 1/1000
1- IHC: Immunohistochemistry
2- IF: Immunofluorescence
3- IB: Immunoblot
 All antibodies were used in BSA 0,3% except the ones marked 4 (BSA 3%) and 5 (BSA 4% + 0.04 Tween-20)
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Supplementary Methods
Transfection and lentiviruses production
Transient transfection of vectors was performed with Lipofectamine 2000 
(Invitrogen) according to manufacturer's instructions. 
For lentivirus production, HEK293T cells were transfected with lentiviral 
expression vectors, envelope plasmid pVSV.G, and packaging plasmid 
pHR'82ΔR at a ratio 2:1:1. Stable expression of Luciferase was carried out by 
lentiviral infection of U87-MG cells and selection in 6 μg/ ml of Hygromycin. 
For RNA interference the CCND1 MISSION shRNAs TRCN0000026838 and 
TRCN0000026839 cloned in a pLKO.1-puro were obtained from Sigma.
The YFP-PBD vector was obtained from J. Swanson via Addgene.
Expression vectors. Site-directed mutagenesis.
Standard PCR-mediated site-directed mutagenesis was used to obtain the 
different mutant alleles of Ccnd1, Rgl2 and Pxn. The 3’ end of the K-Ras ORF 
containing the CAAX motif (GGC TGT GTG AAA ATT AAA AAA TGC ATT ATA 
ATG TAA; aa179–189) was fused to the 3’ end of the CCND1 and RGL2 human 
ORFs. To obtain the non-phosphorylatable and phosphomimetic mutants of 
mouse Paxillin (IMAGE ID 5309957 clone from Source BioScience) were used 
the following primers: 
GCGCCACTGCCCGTGTACAGCTC/CGGAGGCTGCTGGTGAGCGT for S83A; 
GCGCCCCTTTATGGCATCCCAGA/CAGGGCTCCAGGCAAGGGGGG for S178A; 
CCGGTGTACAGCTCCAGTGCTAA/TAGTGGCTCCGGAGGCTGCTGGTGAGCGT for S83E;
GAGCCCCTTTATGGCATCCCAGA/GAGGGCTCCAGGCAAGGGG for S178E.
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Firefly luciferase gene (Fluc) was cloned under the control of the UBI promoter 
in the pLKO.1 hygromycin lentivirus.    
Immunohistochemistry (IHC)
Paraffin blocks of human tumor tissue and mouse tissue samples were sectioned 
at a thickness of 3μm, dried for 1 hour at 65°C before de-parafinization, 
rehydration, and epitope retrieval in the Pre-Treatment Module, PT LINK (Dako, 
Glostrup, Denmark) at 95°C for 20 minutes in 50mM Tris/EDTA buffer, pH 9. 
Before staining the sections, endogenous peroxidase was blocked. Samples 
were visualized with the EnVision FLEX Detection Kit (Dako, Glostrup, Denmark) 
using diaminobenzidine chromogen as a substrate. Slides were counterstained 
with hematoxylin. Negative controls were obtained without the addition of the 
primary antibody. Primary antibodies are described in Supplementary Table 1.
Ral pull-down assay
Cell lysates were obtained from one 100mm plate of transfected GBM cells. The 
lysis buffer used was 50mM Tris pH 7.5, 200mM NaCl, 2.5mM MgCl2, 2.5mM 
DTT, 1% Triton and protease and phosphatase inhibitors. An aliquot of 0.6ml of 
cell lysate was incubated with 10μg of RalBP1 beads for 30 min at 4°C and, after 
several washes, agarose beads were resuspended in 2x Laemmli buffer. 
Samples were separated by SDS-PAGE, transferred to PVDF membranes, and 
immunoblotted.
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Cell culture methods
For proliferation assay, 15000 cells/well were seeded on a 24-well plate in 
triplicates. After 36 or 72 hours of treatment, cells were trypsinized and counted 
in a Neubauer’s chamber. For cell viability determination, 0.2% Trypan Blue was 
added before counting. 
Proliferation and viability were also determined with MTT assay. Cells were 
incubated at 37 °C 5% CO2 during 1 hour with MTT at 1 mg/ml in darkness. Then, 
media was removed and DMSO was added into the wells to dissolve formazan 
crystals produced by living cells. Absorbance was read at 595 nm wavelength. 
To measure cell spreading, petri dishes were coated overnight at 4 °C with a 
5 μg /ml solution of fibronectin (Invitrogen) in PBS. Forty-eight hours after 
infection/transfection, cells were trypsinized and seeded in serum-free medium in 
the fibronectin-coated 35-mm well plates. Cells were incubated for one hour, fixed 
with 2% PFA, and spread cells were counted (n≥150 green cells were evaluated 
in each independent experiment). Round and bright cells were considered 
unspread.
We performed cell invasion assays with infected GBM cells. Briefly, 6.5-mm filters 
of 8.0 pore size (Transwell, Corning) were coated with Matrigel (full factor, BD 
Biosciences) in the bottom side. Then, infected cells (1-2×104) were seeded in 
the upper side of the filter. Afterwards, filters were loaded with DMEM 10% serum 
and incubated in 24-well plates containing serum-free medium for eight hours. 
Under these conditions, some cells migrate from the upper to the bottom side of 
the filter invading the Matrigel. The remaining cells at the upper side of the filter 
were removed, and Matrigel-embedded cells were fixed and stained with 
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Hoescht. We have counted all cells in the filter extension with the Image J 
software. 
Statistical analyses
For mice studies (Fig. 6 and Supplementary Fig. S6), we have used the Ene 3.0: 
a program to calculate sample size. This software was developed by the 
Department of Applied Statistics of Autonomous University of Barcelona and is 
distributed by GlaxoSmithKline. No specific method of randomization was used 
but the group allocation was done randomly. 
For the experiment in Figure 3, we inoculated four animals with U87-MG cells 
infected with Ccnd1-HA (two animals were inoculated with PBS as background 
controls). For the experiment in Figure 6, groups of 11-12 animals were 
inoculated with U87-MG-luciferase-GFP cells, U87-MG-luciferase-GFP-Ccnd1-
HA cells or U87-MG-luciferase-GFP-Ccnd1-CAAX-HA cells. Some animals died 
during anesthesia and others were also discarded by the misleading location of 
the tumor. In those animals, the inoculated cells were scattered through the 
meninges and the tumor developed extra-cranially. Finally, we have analyzed 
three animals in figure 3 (n=3) and nine animals for each condition in figure 6 and 
supplementary figure 6 (n=27).
We have analyzed the differences in number of tumor-evaded cells by Kruskal-
Wallis non-parametric test and Dunn’s multiple comparison post-test. To assess 
the significance in the differences in the number of disseminated tumors, we have 
performed a Fisher’s exact test. 
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MGMT methylation
The DNA of the samples were obtained from GBM cell cultures and subjected to 
a bisulfite treatment (MethylCode ™ Bisulfite Conversion Kit, MECOV50 
ThermoFisher) prior to amplification by PCR. A single fragment covering a part 
of the promoter region is amplified and the degree of methylation is analyzed by 
a pyrosequencing reaction (MGMT Pyro Kit, ID: 970061 Qiagen).
TCGA data analyses
To analyze the clinical relevance of our model, we have obtained diagnosis, 
grading, survival and gene status data of 669 patients with diffuse gliomas  from 
The Cancer Genome Atlas Project (TCGA-GBMLGG) using the GlioVis platform 
(http://gliovis.bioinfo.cnio.es/). For different genes codifying downstream targets 
of cytoplasmic Ccnd1, we have determined the percentage of amplifications 
(Amp), copy number increase (Gain), heterozygous loss (Hetloss) and 
homozygous deletions (Homdel) in two different groups, IDH1 wild type and 
mutant samples. 
By using the same glioma source, we have designed a study to confirm the 
relevance of Ccnd1-Cdk4 activity in glioma prognosis. First, we have chosen as 
standard population a subset of 173 IDH-mutant samples all of them wild type 
diploids for CCND1/2/3, CDK4/6, CDKN2A/B, RAC1 and RALA. Then, we have 
selected other samples with the same background only changing either CCND1 
copy number gain (n=14) or CDKN2A/B homozygous deletion (n=14). Both, 
CCND1 gain and CDKN2A/B homozygous deletion should stimulate Cdk4/6 
activity. Overall survival in those three conditions was analyzed by the Kaplan–
Meier method and compared with a log- rank test. 
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